---
title: "Wegovy (semaglutide) in chronic weight management: Access and coverage questions"
description: "Access and coverage questions on Wegovy (semaglutide) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Cost and coverage and Patient support. Questions: How much does Wegovy cost without insurance? How much does Wegovy cost with commercial insurance and the savings offer? Is there a Wegovy savings card? How can I check if a patient’s insurance covers Wegovy? 9 further questions follow. 13 questions quoted from 9 sources."
canonical: "https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/access-and-coverage"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Wegovy (semaglutide) in chronic weight management: Access and coverage questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Wegovy](https://www.novo-pi.com/wegovy.pdf)

Questions that apply to every indication of Wegovy are on [Wegovy (semaglutide), all indications](https://www.evicenter.com/medical-information/wegovy).

## Cost and coverage

<a id="wegovy-cost-without-insurance"></a>

### How much does Wegovy cost without insurance?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Pen Self-Pay
> Savings
>
> First two doses of 0.25 mg
> and 0.5 mg
>
> $199 per month*
>
>
> Then $349 per month
>
> 1 mg, 1.7 mg, and
> 2.4 mg doses
>
> $349 per month*
>
> 7.2 mg dose
>
>
>
> $399 per month*”

Source: [WEGOVY: Wegovy® (semaglutide) Savings Card Access & Info for Patients, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/patient-savings.html#:~:text=Pen%20Self%2DPay,%24399%20per%20month%2A)

> “*Patients new to the Wegovy<sup>®</sup> Savings offer or NovoCare<sup>®</sup> Pharmacy pay $199 for each month of 0.25 mg & 0.5 mg. Offer for 2 monthly fills through December 31, 2026, then $349 per month for Wegovy<sup>®</sup> 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg and $399 per month for Wegovy<sup>®</sup> HD 7.2 mg. One month defined as 1 box of 4 pens of Wegovy<sup>®</sup>. Eligibility and restrictions apply. Novo Nordisk reserves the right to modify or cancel this program at any time. See full terms at WegovyTerms.com and NovoCarePharmacyTerms.com.”

Source: [WEGOVY: Wegovy® (semaglutide) Savings Card Access & Info for Patients, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/patient-savings.html#:~:text=%2APatients%20new%20to%20the,terms%20at%20WegovyTerms.com%20and%20NovoCarePharmacyTerms.com.)

> “Pill Self-Pay
> Savings
>
> 1.5 mg dose
>
>
>
> $149 per month*
>
>
> 4 mg dose
>
>
>
> $199 per month*
>
>
>
> 9 mg and 25 mg
> doses
>
>
> $299 per month*”

Source: [WEGOVY: Wegovy® (semaglutide) Savings Card Access & Info for Patients, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/patient-savings.html#:~:text=Pill%20Self%2DPay,%24299%20per%20month%2A)

On the page, select: Pill

> “*Self-pay pricing varies by dose. One month defined as 1 bottle of 30 tablets. Eligibility and restrictions apply. Novo Nordisk reserves the right to modify or cancel this program at any time. See full terms at WegovyTerms.com and NovoCarePharmacyTerms.com.”

Source: [WEGOVY: Wegovy® (semaglutide) Savings Card Access & Info for Patients, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/patient-savings.html#:~:text=%2ASelf%2Dpay%20pricing%20varies%20by%20dose.,terms%20at%20WegovyTerms.com%20and%20NovoCarePharmacyTerms.com.)

On the page, select: Pill

Note: The first two passages are from the Pen tab and the last two from the Pill tab of the patient savings page.

<a id="wegovy-cost-with-insurance"></a>

### How much does Wegovy cost with commercial insurance and the savings offer?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “With the Wegovy<sup>®</sup> Savings Offer, commercially insured patients pay as little as ~$25 per month<sup>†</sup>”

Source: [WEGOVY: Obesity Prescription Savings Card Offers for Patients | novoMEDLINK™, captured 2026-11-12](https://www.novomedlink.com/obesity/patient-support/savings-coverage/savings-card.html#:~:text=for%207.2%20mg-,With%20the,as%20little%20as%20~%2425%20per)

> “<sup>†</sup>Pay as little as $25, subject to a maximum savings of $100/month. Eligibility and restrictions apply. Government beneficiaries excluded. Month defined as 1 box of 4 pens of Wegovy<sup>®</sup> and 1 bottle of 30 tablets of Wegovy<sup>®</sup>. Novo Nordisk reserves the right to modify or cancel this program at any time. See full terms at WegovyTerms.com and NovoCarePharmacyTerms.com.”

Source: [WEGOVY: Obesity Prescription Savings Card Offers for Patients | novoMEDLINK™, captured 2026-11-12](https://www.novomedlink.com/obesity/patient-support/savings-coverage/savings-card.html#:~:text=as%20little%20as%20%2425%2C%20subject,terms%20at%20WegovyTerms.com%20and%20NovoCarePharmacyTerms.com.)

> “With the Wegovy<sup>®</sup> Savings Offer, commercially insured patients pay as little as $25 per month<sup>†</sup>”

Source: [WEGOVY: Obesity Prescription Savings Card Offers for Patients | novoMEDLINK™, captured 2026-11-12](https://www.novomedlink.com/obesity/patient-support/savings-coverage/savings-card.html#:~:text=Commercial%20Insurance%20Savings-,With%20the,as%20little%20as%20%2425%20per)

> “<sup>†</sup>30-day supply for pill equivalent to 1 month of treatment. One month defined as 1 bottle of 30 tablets. Pay as little as $25, subject to a maximum savings of $100/month. Government beneficiaries excluded. Novo Nordisk reserves the right to modify or cancel this program at any time. See WegovyTerms.com for full terms.”

Source: [WEGOVY: Obesity Prescription Savings Card Offers for Patients | novoMEDLINK™, captured 2026-11-12](https://www.novomedlink.com/obesity/patient-support/savings-coverage/savings-card.html#:~:text=supply%20for%20pill%20equivalent%20to,See%20WegovyTerms.com%20for%20full%20terms.)

Note: The first two passages are from the Wegovy injection offer and the last two from the Wegovy tablets offer on the savings card offers page of novoMEDLINK.

<a id="wegovy-savings-card"></a>

### Is there a Wegovy savings card?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “<sup>†</sup>Pay as little as $25, subject to a maximum savings of $100/month. Government beneficiaries excluded. Month defined as 1 box of 4 pens of Wegovy<sup>®</sup>. Eligibility and restrictions apply. Novo Nordisk reserves the right to modify or cancel this program at any time. See full terms at WegovyTerms.com and NovoCarePharmacyTerms.com.”

Source: [WEGOVY: Wegovy® (semaglutide) Savings Card Access & Info for Patients, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/patient-savings.html#:~:text=as%20little%20as%20%2425%2C%20subject,terms%20at%20WegovyTerms.com%20and%20NovoCarePharmacyTerms.com.)

> “Commercially insured or self-paying patients can download a savings card for the Wegovy<sup>®</sup> pen or the Wegovy<sup>®</sup> pill to use at retail pharmacies.”

Source: [WEGOVY: Frequently Asked Questions, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/resources/frequently-asked-questions.html#:~:text=Commercially%20insured%20or%20self%2Dpaying%20patients,to%20use%20at%20retail%20pharmacies.)

This passage is in a collapsed section of the page; select: How can my patients save on the cost of Wegovy® and Wegovy® HD?

<a id="wegovy-check-coverage"></a>

### How can I check if a patient’s insurance covers Wegovy?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “At WegovyCoverage.com, verify your patient’s coverage in as little as 90 seconds”

Source: [WEGOVY: Wegovy® (semaglutide) Savings Card Access & Info for Patients, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/patient-savings.html#:~:text=At%20WegovyCoverage.com%2C%20verify%20your%20patient%E2%80%99s%20coverage%20in%20as%20little%20as%2090%20seconds)

> “Use our formulary tool to see which plans in your area include Wegovy<sup>®</sup> for your patients. Formulary status is believed to be accurate at the time of update but cannot be guaranteed.”

Source: [WEGOVY: Wegovy® (semaglutide) Insurance & Formulary Coverage, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/understanding-wegovy-access.html#:~:text=Use%20our%20formulary%20tool%20to,update%20but%20cannot%20be%20guaranteed.)

> “Patients can learn more about their Wegovy<sup>®</sup> coverage by contacting their employer, health plan, PBM, or retail pharmacy.”

Source: [WEGOVY: Wegovy® (semaglutide) Insurance & Formulary Coverage, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/understanding-wegovy-access.html#:~:text=Patients%20can%20learn%20more%20about,plan%2C%20PBM%2C%20or%20retail%20pharmacy.)

Note: The first passage is from the patient savings page and the others from the understanding access page of the Wegovy HCP site.

<a id="wegovy-medicare"></a>

### Does Medicare cover Wegovy for weight loss?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Eligible Medicare patients can access all doses of Wegovy<sup>®</sup> pen & pill  
> for only $50 per month.”

Source: [WEGOVY: medicare-glp-1-bridge-process-resource-flashcard.pdf, page 1, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/patient-support/product/documents/medicare-glp-1-bridge-process-resource-flashcard.pdf#page=1)

> “When<sup>1</sup>: Available as of July 1, 2026”

Source: [WEGOVY: medicare-glp-1-bridge-process-resource-flashcard.pdf, page 1, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/patient-support/product/documents/medicare-glp-1-bridge-process-resource-flashcard.pdf#page=1)

> “*The Medicare GLP-1 Bridge Program is a nationwide, short-term CMS program designed to cover select weight management drugs for Medicare Part D 
> beneficiaries.<sup>1</sup>”

Source: [WEGOVY: medicare-glp-1-bridge-process-resource-flashcard.pdf, page 1, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/patient-support/product/documents/medicare-glp-1-bridge-process-resource-flashcard.pdf#page=1)

> “<sup>†</sup>Terms apply. For eligible Medicare patients prescribed Wegovy<sup>®</sup> for a covered FDA-approved indication. Eligibility criteria will be determined by CMS. 
> This information is not a guarantee of coverage. Month defined as 1 box of 4 pens of Wegovy<sup>®</sup> and 1 bottle of 30 tablets of Wegovy<sup>®</sup>. Visit https://www.cms.gov/
> medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge to learn more.<sup>1,2</sup>”

Source: [WEGOVY: medicare-glp-1-bridge-process-resource-flashcard.pdf, page 1, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/patient-support/product/documents/medicare-glp-1-bridge-process-resource-flashcard.pdf#page=1)

> “Medicare GLP-1 Bridge Program eligibility<sup>1</sup>
>
> Medication prescribed for weight management, in combination with current and ongoing lifestyle modification consistent with the applicable FDA-approved label
>
> Enrolled in a Medicare Part D plan (stand-alone PDP or MA PD), including Special Needs Plans (SNPs), employer/union group waiver plans (EGWPs), Limited Income Newly Eligible Transition (LI NET), and dual-eligible beneficiaries who are enrolled in eligible Part D plan types
>
> ≥18 years of age
>
> BMI ≥35 kg/m<sup>2</sup>
>
> or BMI ≥30 kg/m<sup>2</sup> + 1 or more of the following comorbidities
>
> Uncontrolled HTN,<sup>‖</sup> HFpEF, CKD Stage 3a, or above
>
> or BMI ≥27 kg/m<sup>2</sup> + 1 or more comorbidities
>
> Pre-diabetes, previous stroke/MI, symptomatic PAD”

Source: [WEGOVY: Wegovy® (semaglutide) Savings Card Access & Info for Patients, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/patient-savings.html#:~:text=pen%20and%20pill-,Medicare%20GLP%2D1%20Bridge%20Program,Pre%2Ddiabetes%2C%20previous%20stroke%2FMI%2C%20symptomatic%20PAD)

> “<sup>‖</sup>Uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with 2 antihypertensive medications).”

Source: [WEGOVY: Wegovy® (semaglutide) Savings Card Access & Info for Patients, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/patient-savings.html#:~:text=hypertension%20%28defined%20as%20systolic%20blood,treatment%20with%202%20antihypertensive%20medications%29.)

> “Patients are not eligible if:
> •	They are currently receiving a GLP-1 through their Part D plan or they will be receiving a GLP-1 for a Part D covered  
> FDA-approved indication”

Source: [WEGOVY: medicare-glp-1-bridge-process-resource-flashcard.pdf, page 2, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/patient-support/product/documents/medicare-glp-1-bridge-process-resource-flashcard.pdf#page=2)

> “Medicare GLP-1 Bridge patients do not need a prior authorization when switching between Wegovy<sup>®</sup> pen and pill”

Source: [WEGOVY: Wegovy® (semaglutide) Savings Card Access & Info for Patients, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/patient-savings.html#:~:text=Medicare%20GLP%2D1%20Bridge%20patients%20do,pen%20and%20pill)

Note: The first four passages and the ineligibility criteria are from the Medicare GLP-1 Bridge Process Resource Flashcard that the patient savings page links.

<a id="wegovy-prior-authorization"></a>

### Does Wegovy require prior authorization?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “A prior authorization may be required if patient is using commercial insurance”

Source: [WEGOVY: Prescribing Wegovy® Pen or Pill, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/prescribing.html#:~:text=A%20prior%20authorization%20may%20be%20required%20if%20patient%20is%20using%20commercial%20insurance)

> “On formulary: A PA for Wegovy<sup>®</sup> may be required.”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=On%20formulary%3A%20A%20PA%20for,may%20be%20required.)

Note: The first passage is from the prescribing page and the second from the prior authorization page of the Wegovy HCP site.

<a id="wegovy-prior-authorization-checklist"></a>

### What should a Wegovy prior authorization request include?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Prior authorizations (PAs) vary by plan, and when submitting the requested forms for your patient’s Wegovy<sup>®</sup> prescription you should:
>
> Provide accurate, complete, and detailed information
>
> Clarify with the patient’s payer what clinical documentation, if any, is required
>
> Understand that inaccurate or incomplete documentation may result in a delayed or denied claim”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=Prior%20authorizations%20%28PAs%29%20vary%20by,a%20delayed%20or%20denied%20claim)

> “Be sure to accurately include:
>
> Patient information
>
> Including correct full name, date of birth, and insurance numbers
>
>
> Patient history
>
> Including most recent BMI, comorbidities, and previous therapies
>
>
> Provider and facility information
>
> Your correct data, such as contact information and NPI, are imperative”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=Be%20sure%20to%20accurately%20include%3A,information%20and%20NPI%2C%20are%20imperative)

> “Treatment plan with Wegovy<sup>®</sup>
>
> This would include lifestyle modification, therapy goals, and medication details
>
> Reauthorization considerations
>
> If an insurance plan requires reauthorizations every 6 or 12 months, you may need to submit any change in a patient’s health”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=Treatment%20plan%20with,change%20in%20a%20patient%E2%80%99s%20health)

<a id="wegovy-prior-authorization-denial"></a>

### Why are Wegovy prior authorizations denied?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “What are common reasons for denial?
>
> The patient does not meet the clinical criteria
> Wegovy<sup>®</sup> is not covered or non-formulary or weight loss is a benefit exclusion
> The patient did not try and fail a formulary alternative
> An invalid diagnosis code was submitted
> Missing information or information was not received in time”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=What%20are%20common%20reasons%20for,was%20not%20received%20in%20time)

<a id="wegovy-prior-authorization-appeal"></a>

### What can be done after a Wegovy prior authorization is denied?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Submit a Letter of Appeal. A peer-to-peer discussion with a medical director or a third-level appeal may help.”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=Submit%20a%20Letter%20of%20Appeal.,a%20third%2Dlevel%20appeal%20may%20help.)

> “Discuss additional options, including self-pay or via the NovoCare<sup>®</sup> support programs”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=Discuss%20additional%20options%2C%20including%20self%2Dpay,support%20programs)

<a id="wegovy-not-covered"></a>

### What are the options if insurance does not cover Wegovy?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Not on formulary: Wegovy<sup>®</sup> is not included on the insurance plan’s list of covered medications.
>
> Submit a formulary exception request and a Letter of Medical Necessity”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=Not%20on%20formulary%3A,a%20Letter%20of%20Medical%20Necessity)

> “Benefit exclusion: Obesity is not covered under the health insurance plan and will most likely receive an automatic denial; however, for appropriate patients, major adverse cardiovascular events (MACE) risk reduction may be a covered diagnosis.”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=Benefit%20exclusion%3A%20Obesity%20is%20not,may%20be%20a%20covered%20diagnosis.)

> “Patients without coverage can fill prescriptions through NovoCare<sup>®</sup> Pharmacy”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=Patients%20without%20coverage%20can%20fill,Pharmacy)

> “This information is provided for educational purposes only. Insurance coverage may vary by health plan, patient, and setting of care. Novo Nordisk does not guarantee coverage.”

Source: [WEGOVY: Wegovy® (semaglutide) Prior Authorization Criteria & Form, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html#:~:text=This%20information%20is%20provided%20for,Nordisk%20does%20not%20guarantee%20coverage.)

<a id="wegovy-cvs-caremark"></a>

### Is Wegovy covered by CVS Caremark?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Wegovy<sup>®</sup> is a preferred GLP-1 obesity medicine on CVS Caremark<sup>®</sup>*<sup>†‡</sup>
>
> Wegovy<sup>®</sup> is preferred on these template formularies:
>
> CVS Caremark<sup>®</sup> Performance Drug List – Standard Control
>
> CVS Caremark<sup>®</sup> Advanced Control Formulary<sup>®</sup>
>
> CVS Caremark<sup>®</sup> Value Formulary
>
> Aetna<sup>®</sup>
>
> *Formulary data are provided by Managed Markets Insight & Technology, LLC (MMIT) and are current as of May 1, 2025. Because formularies do change and many health plans offer more than one formulary,please check directly with the health plan to confirm coverage for individual patients.
>
> <sup>†</sup>Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative costs. Formularycoverage does not imply a product endorsement.
>
> <sup>‡</sup>Novo Nordisk defines formulary coverage as Preferred, Covered, or Covered w/ Restrictions. Preferred = Product is covered on preferred formulary with no material restrictions.”

Source: [WEGOVY: Wegovy® (semaglutide) Insurance & Formulary Coverage, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/understanding-wegovy-access.html#:~:text=is%20a%20preferred%20GLP%2D1%20obesity,formulary%20with%20no%20material%20restrictions.)

Note: The page dates this CVS Caremark listing to MMIT formulary data current as of May 1, 2025; formulary status should be confirmed with the plan.

<a id="wegovy-compounded-semaglutide"></a>

### Is compounded semaglutide the same as Wegovy?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Wegovy<sup>®</sup> is FDA approved.
>
> Compounded “semaglutide” is not.”

Source: [WEGOVY: Compounded “Semaglutide” vs Wegovy® (semaglutide) 2.4 mg injection | NovoMedlink®, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/resources/compounded-semaglutide-information.html#:~:text=is%20FDA%20approved.,Compounded%20%E2%80%9Csemaglutide%E2%80%9D%20is%20not.)

> “the FDA-approved Wegovy<sup>®</sup> pill has technology designed to facilitate absorption of semaglutide.<sup>1</sup> Without it, there's no guarantee that compounded options will be absorbed or effective.<sup>2</sup>”

Source: [WEGOVY: Compounded “Semaglutide” vs Wegovy® (semaglutide) 2.4 mg injection | NovoMedlink®, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/resources/compounded-semaglutide-information.html#:~:text=the%20FDA%2Dapproved,options%20will%20be%20absorbed%20or)

Note: These statements are from the compounded semaglutide information page of the Wegovy HCP site; the Prescribing Information does not discuss compounded products. The absorption statement concerns Wegovy tablets and is the manufacturer's.

## Patient support

<a id="wegovy-wegotogether-support"></a>

### Is there a Wegovy patient support program?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “To complement, not replace, your care, the WeGoTogether<sup>®</sup> app was developed by Novo Nordisk, the maker of Wegovy<sup>®</sup>, to support your patients as they work to lose weight and keep it off.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=To%20complement%2C%20not%20replace%2C%20your,weight%20and%20keep%20it%20off.)

> “Rooted in behavior change to help patients reach their goals, patients learn skill building in areas like goal setting, habit formation, nutrition, and handling social situations around food.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Rooted%20in%20behavior%20change%20to,handling%20social%20situations%20around%20food.)

> “WeGoTogether<sup>®</sup> is a program with behavior change resources designed to help your patients get started and stay on track with Wegovy<sup>®</sup>.”

Source: [WEGOVY: Frequently Asked Questions, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/resources/frequently-asked-questions.html#:~:text=is%20a%20program%20with%20behavior,and%20stay%20on%20track%20with)

This passage is in a collapsed section of the page; select: Does Novo Nordisk offer a support program for Wegovy® and Wegovy® HD patients?

## Related pages
- [Medical information: Wegovy (semaglutide): Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/safety)
- [Specific populations](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/dosing-and-administration)
